Midi Health Revenue, Valuation, Funding & Investors

Forward is a San Francisco-headquartered healthcare provider founded in 2016 by Adrian Aoun and former Google and Uber leaders. It deploys sensors, mobile apps, and AI for proactive health monitoring in membership-based clinics. Backed by First Round Capital, Eric Schmidt, Marc Benioff, Joe Lonsdale, Joshua Kushner, and Garrett Camp, the company operates facilities in California and beyond, emphasizing preventive care over traditional visits.

Hims & Hers is a San Francisco-headquartered telehealth platform connecting patients with licensed providers for treatments in hair loss, erectile dysfunction, mental health, dermatology, and weight management. Founded in 2017 and public on NYSE since 2021, it serves 1.5 million subscribers through its proprietary electronic health record system. Partnerships with Ochsner Health, Mount Sinai, and Privia Health enable hybrid virtual and in-person care, with Hers brand launched in 2018 expanding women's health options like skincare and birth control.

Calibrate is a New York-headquartered telehealth company offering a virtual program for metabolic health and weight management. Launched in 2020, it pairs FDA-approved GLP-1 medications like semaglutide with personalized coaching, nutrition plans, and behavioral therapy delivered via app and video sessions. The program targets adults with obesity, emphasizing long-term habit formation through weekly check-ins and biomarker tracking. Calibrate serves thousands of members nationwide and collaborates with obesity specialists from institutions like Mount Sinai.

Pristyn Care is a healthcare startup in India specializing in daycare procedures using technology-enabled processes. It covers surgeries like piles, hernia, and cataracts through in-house networks. Operating in multiple cities including Bangalore and Delhi, the company integrates teleconsultations and end-to-end care delivery.

Found is a San Francisco-headquartered telehealth company founded in 2019 that prescribes GLP-1 medications like semaglutide for weight loss. It partners with U.S. pharmacies for compounded drugs and serves members across 50 states with virtual coaching and tracking tools.

Workit Health is a telemedicine provider specializing in substance use disorder treatment through its mobile app. Based in San Francisco, California, the platform delivers medication-assisted therapy, individual counseling, group sessions, psychiatric care, and recovery coaching compliant with ASAM standards. Founded in 2016, it serves patients in 38 U.S. states, treating over 25,000 individuals annually with evidence-based protocols including buprenorphine prescriptions and cognitive behavioral therapy. Workit Health partners with employers and health plans for accessible outpatient care.

Slingshot AI is a New York and London-based AI research firm developing tools to expand mental health access amid a 10,000:1 provider shortage. The team builds psychology-informed models for personalized interventions, serving users via apps since 2023 with cross-disciplinary expertise from clinicians and engineers.

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Kooth PLC is a digital mental health provider to the NHS for children and young people by providing a broad range of therapeutic tools and interventions. The company's online platform provides Self-help tools and content, Community for Peer-to-Peer Support and Professional Counselling. It provides individuals with free access to mental health support, funded by healthcare systems, insurers, businesses or charities. The company's operations take place in the UK and the United States.

iXensor Co Ltd is a Taiwan based company involved in research and development, manufacturing and sales of medical equipment. Its PixoTest technology utilizes the lighting and image sensing module of the smartphone or mobile device to detect the color change reaction on the biochemical test strip. This enables the users to monitor their conditions of diabetes, cardiovascular diseases, women health problems, or infectious diseases.

Maven Clinic is a virtual clinic for women's and family health, founded in 2014 by CEO Kate Ryder, offering telehealth and financial reimbursement for care spanning fertility, maternity, pediatrics, and menopause. Employers and health plans, including Amazon, Microsoft, and AT&T, offer Maven's platform as a benefit covering the full reproductive lifecycle from preconception through menopause. The company has reported clinical outcomes such as lower C-section and NICU admission rates among members using its programs.

DocPlanner is a healthcare software provider streamlining patient-doctor interactions. Warsaw-headquartered and founded in 2012, it runs online marketplaces under brands like ZnanyLekarz across 13 countries in Europe and Latin America. DocPlanner offers appointment booking, reviews, scheduling, teleconsultations, and clinic management tools, with advanced optimization via the TuoTempo suite for large institutions. Offices span Barcelona, Istanbul, Rome, Mexico City, Munich, Berlin, Rio, and Amsterdam.

Evidation Health is a San Mateo-headquartered company founded in 2012 that measures health outcomes through everyday activities via its Achievement platform. The platform enables participation in research and health programs with partners in healthcare and pharmaceuticals. Evidation maintains offices worldwide and emphasizes user-controlled health data for studies beyond clinical settings.

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.